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INTRODUCTION 
In recent years, there has been important progress in 
our knowledge of bacterial resistance to antibiotics. 
The availability of an increasing number of antibiotics 
has allowed more precise individualization of resistance 
phenotypes, and enzyme inhibitors have provided clues 
concerning certain mechanisms of resistance. Study of 
the biochemical mechanisms of resistance of strains 
representative of the various phenotypes has led to 
elucidation of cross-resistance, and examination of large 
numbers of clinical isolates has provided information 
on co-resistance to antibiotics. Detailed analysis of the 
bacteriostatic and bactericidal activity of antibiotics, 
alone or in combination, has indicated the limits of in 
vitro antimicrobial susceptibility tests in the detection 
of resistance resulting in clinical failure. The goal of 
combined molecular and therapeutic interpretation of 
susceptibility tests is to provide an improved logical 
basis for decision-making in antibiotic therapy by 
taking into account the recent progress in the 
understanding of bacterial resistance. 
PRINCIPLE 
The molecular analysis and therapeutic interpretation, 
designated ‘interpretive reading’, of the in vitro anti- 
biotic susceptibility tests (the antibiogramme) consists 
of three steps: (1) characterization of the resistance 
phenotype with a judicious assortment of antibiotics 
belonging to the same family or the same class; (2) 
deduction from the observed phenotype of the 
corresponding biochemical mechanism of resistance; 
and (3) inference fiom the deduced mechanism of the 
predicted resistance phenotype. 
As can be seen from the examples provided in 
Table 1, this approach is most useful for detection 
and characterization of low-level resistance due to 
production of a single enzyme. It also applies to 
combined phenotypes resulting fiom the coexistence in 
the same host of several mechanisms conferring 
resistance to antibiotics belonging to the same group. 
However, the study of strains harboring two cross- 
resistance determinants indicated that in general the 
genes contribute, in an additive fashion, to the degree 
of antibiotic resistance, resulting in unambiguous and 
easily detectable phenotypes. 
RATIONALE 
Antibiotics are not lonely individuals but members of tight 
families 
The vast majority of antibiotics used in human therapy 
can be assigned to a few families, such as p-lactams, 
aminoglycosides, quinolones, etc., whlch, in turn, can 
be divided into classes (for example, p-lactams include 
benzylpenicillin, the methicillin class, amino-carboxy-, 
acylureido-, and amidinopenicillins, carbapenems, 
cephalosporins and monobactams). Since group assign- 
ment is based on structural criteria, antibiotics belong- 
ing to the same family or the same class are closely 
related. This implies that they have similar modes of 
action and spectra of activity, and that they are likely to 
be affected, albeit in certain cases to various degrees, by 
the same resistance mechanisms (cross-resistance). 
Certain families such as macrolide, lincosamide and 
streptogramin (MLS) antibiotics, although chemically 
distinct, have the same intracellular target and can 
therefore be considered, in view of interpretation of in 
vitro tests, as a single functional group. 
As a consequence, the results of in vitro anti- 
biotic susceptibility tests (the antibiogramme) must be 
analyzed simultaneously for antibiotics belonging to 
the same family or class and not individually for every 
antibiotic considered separately. This notion has clear 
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Table 1 
Host Observed phenotypeJ Inferred mechanismh Predicted phenotype‘ 
Examples of interpretive reading of antibiogrammes 
Gram-positive coccid KmRTmSGmSAk’ 
KmRTmRGmsAk’ 
GmR 
APH(3‘) KmRTm‘GGm5Ak’~K 
ANT(4‘) KmRTmRGm‘Ak”R 
APH(Z”)-AAC(6’) Resistant to all aniinoglycosides 
Streptococcus EmK rRNA rnethylase Resistant to all macrolides 
Enterobacteriaceae Amino, carboxypenicillinsR TEM1-2, SHVl Acylureidopenicillins’/R, mecillinamR, 
Amino, carboxypenicillinsR, Extended-spectrum Resistant to all p-lactams except 
synergy clavulanic acid P-lactamase cephamycins, carbapenems, moxalactam 
+ cefotaxime or ceftazidime 
’Ak, amikacin; Gm, gentamicin; Em, erythromycin; Km, kanamycin; Tm, tobramycin; R ,  resistant; S, susceptible. 
‘AAC, aminoglycoside acetyltransferase; ANT, aminoglycoside nucleotidyltransferase; APH, aminoglycoside phosphotransferase. 
‘I, intermediate. 
dGentamicin and sisomicin are equivalent except against Enferococcusfaecium because of the chromosomally encoded AAC(6’), which confers 
resistance to the latter but not to the former antibiotic. 
implications for the selection of antibiotics that should 
be used for in vitro susceptibility testing. 
Limits of antimicrobial susceptibility tests 
Partly for technical reasons, in particular limits of 
optical scanning devices resulting in poor quantification 
of bacterial populations lower than lo6 to lo7 CFU/ 
mL, routine susceptibility tests explore only the 
bacteriostatic activity of antibiotics. Under these con- 
ditions, decreases in activity of certain antibiotics 
against certain strains cannot be detected. This lack of 
apparent resistance is independent of the technique 
used, since it is intrinsic to the biochemical mechanism 
of resistance itself. These limitations are observed 
generally with antibiotics that are poor substrates for 
inactivating enzymes. For example, although bacterio- 
static activity of amikacin and netilmicin against Gram- 
positive cocci harboring a 3’-phosphotransferase or a 
2”-phosphotransferase-6’-acetyltransferase is apparently 
unaffected, the bactericidal activity of the two 
antibiotics is abolished and they no longer synergize p- 
lactams. They are inactive from a therapeutic point of 
view and the strains should thus be reported as 
intermediate or resistant to both drugs (Table 1). 
Similarly, staphylococci resistant to high levels of 
lincomycin through production of a lincosamide 
nucleotidyltransferase apparently remain susceptible to 
clindamycin. However, the minimum bactericidal 
concentrations (MBCs) of clindamycin against these 
isolates are greatly increased and the strains should be 
considered as resistant. Reducing the lower breakpoint 
that discriminates the susceptible from the intermediate 
and resistant populations of bacteria is therefore of 
no help and would only result in distributing the 
population of susceptible bacteria into two clinical 
categories. These limitations or pitfalls of in vitro tests 
can often be overcome by complementary analysis (e.g. 
use of a chromogenic cephalosporin for the detection 
of p-lactamases) or, as indicated in Tables 1 and 2 
and discussed below, by testing antibiotics not used 
in clinical practice or by interpreting the results 
obtained with other members of the same group of 
antibiotics. 
Co-resistance 
Although they result from distinct biochemical 
mechanisms, certain antibiotic resistance traits often 
co-reside within the same clinical isolate. Apart from 
strain epidemics, this arises following multiple anti- 
biotic pressure, spreads because of favorable epidemio- 
logic conditions and persists due to coordinated 
expression of antibiotic resistance genes that are 
frequently clustered along the genome. Advantage can 
be taken of this physical link between different 
determinants for detection of antibiotic resistance. For 
example, in certain hospitals more than 99% of 
methicillin-resistant Stuphylocncctrs uureus bacteria are 
also resistant to gentamicin. Because of phenotypic 
heterogeneity, the presence of the former type of 
resistance is difficult to ascertain, whereas the latter, due 
to synthesis of the 2”-aminoglycoside phosphotrans- 
ferase-6’-aminoglycoside acetyltransferase bifunctional 
enzyme, is readily detectable. As the degree of cor- 
relation between the two characters is much higher 
than the efficacy of techniques to detect methicillin 
resistance, gentamicin is routinely used in those 
particular ecosystems for detection of resistance to 
methicillin in strains of S. uureus. 
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Table 2 Antibiotics and combinations that detect best certain resistance mechanisms 
Antibiotic Phenotwe Mechanism' Host 
Penicillin+pH indicator Penicillin resistance Penicillinase Gram-positive cocci. 
Haemophilus, Neisseriu 
Staphylococcus 
Streptococcus pneumoniae 
Oxacillin 
Oxacillin 
P-Lactam resistance 
Penicillin resistance 
Additional PBP 
PBP alteration 
Aminopenicillin, 
aminopenicillin + penicillinase inhibitor 
Cefotaxime or cefiazidime 
+penicillinase inhibitor' 
Penicillin resistance Penicillinase Enterobacteria 
P-Lactam (except 
cephamycins and 
carbapenems) resistance 
Extended spectrum p-lactamaseb 
(plasmid-mediated) 
Cefoxitin+cephalosporind 
Clavulanic acid+cephalosporind 
Imipenem+cephalosporind 
Cephamycins, moxalactam+cephalosporind 
Cephalosporin resistance 
Antibiotic resistance 
(chromosome-mediated) 
Cephalosporinase 
Porin alteration 
Cefoxitin Antibiotic resistance Porin alteration Escherichia coli, 
APH(3'), ANT(4') Gram-positive cocci 
APH(2")-AAC(6') 
AAC(2'), AAC(6') Gram-negative bacteria 
AAC(3)-IV 
AAC(3)-1 
APH(3')-VI Acinetobacter 
AAC(3) Pseseudomonas 
Klebsiella 
Kanamycin 
Gentamicin 
2'-N-Ethylnetilmicin+6'-N-ethylnetilmicine 
Apramycin' 
Fortimicin' 
Amikacin+tobramycin 
Netilmicin+tobramycin 
Amikacin resistance 
Aminoglycoside resistance 
Aminoglycoside resistance 
Aminoglycoside resistance 
Aminoglycoside resistance 
Aminoglycoside resistance 
Aminoglycoside resistance 
Erythromycin + lincomycin Inducible MLS resistance Ribosomal methylation Gram-positive cocci 
Nalidixic acid Quinolone resistance DNA gyrase or porin alteration Gram-negative bacteria 
Tinidazole lmidazole resistance Reductase Anaerobes 
"C, aminoglycoside acetyltransferase; ANT, aminoglycoside nucleotidyltransferase; APH, aminoglycoside phosphotransferase; PBP, 
penicillin binding protein. 
bExcept Proteus penneri and I? vulgaris, which resist through production of a cephalosporinase susceptible to penicillinase inhibitors. 
'In case of synergism. 
'Not used in therapy. 
case of indifference 
Clinical categorization is already interpretation 
As mentioned above, limits of in vitro susceptibility 
tests reside in the fact that the increase in MIC of an 
antibiotic due to a resistance mechanism is often low 
and insuflicient to cross the lower barrier of clinical 
categorization. This confirms that there is an important 
loss of information in expressing results obtained in a 
multiple-class system (MICs are usually determined by 
serial twofold dilution of the antibiotic) with three 
(susceptible, intermediate, and resistant) or even two 
(susceptible and resistant) classes. Clearly, 0.006 and 
1 pg/mL of penicdhn are distinct values even though, 
in both cases, the strains could be considered as 
susceptible. A major goal of interpretive reading of in 
vitro tests is better detection of antibiotic resistance 
mechanisms by comparison of the phenotype of the 
clinical isolate with that of a susceptible strain of the 
same species. This approach should thus rely on MIC 
determination, or MIC equivalent in the case of 
automated devices. In addition, since there is no 
international agreement on breakpoints for inter- 
pretation of in vitro antibiotic susceptibility tests (the 
antibiogramme), a system that intends to be universal 
cannot be based on subjective and local criteria, as 
resistance mechanisms and their bacterial hosts are 
similar worldwide. It is noteworthy that in clinical 
practice there are only two categories, success or failure, 
the intermediate category being confined to antibiotics 
with dosages that can be significantly increased (e.g. p- 
lactams but not aminoglycosides). 
Facilitation of resistance 
The attention of the physician should be drawn to 
situations where emergence of resistance can be 
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anticipated. Mutations (e.g. gyrA) leading to high-level 
resistance to nalidixic acid in enterobacteria also confer 
resistance to all other quinolones. However, the degree 
of cross-resistance depends upon the intrinsic activity 
of the drug: fluoroquinolones with only slightly elevated 
MICs remain clinically active. Nevertheless, these 
strains already possess a resistance mechanism and are 
more likely to become resistant to ciprofloxacin under 
monotherapy with ths  antibiotic following a second 
mutational event. Similarly, staphylococci that are 
inducibly resistant to MLS are good candidates for 
constitutive generalized cross-resistance to these 
antibiotics if treated with 16-membered macrolides or 
with lincosamides. 
Carte or menu? 
Under no circumstances can, or even should, all 
commercially available antibiotics be tested. Therefore, 
what are the best criteria for selection of antibiotics that 
have to be tested in vitro? For proper detection and 
characterization of resistance phenotypes, the approach 
proposed here implies the testing of a minimum of 
antibiotics belonging to the same family in the case of 
various resistance mechanisms (e.g. aminoglycosides or 
MLS antibiotics), or of a representative of each class in 
the case of large f a d e s  (e.g. p-lactams). As already 
mentioned, there is often cross-resistance, but to 
various degrees, among antibiotics that are closely 
related in structure. Antibiotics most affected by a 
resistance mechanism, and thus more apt to detect 
resistance, have a lower intrinsic activity compared to 
other members of the family. These drugs should 
therefore be tested, as well as combinations of substrate 
plus enzyme inhibitor or substrate plus inducer of 
enzyme synthesis (Table 2) .  Similarly, antibiotics and 
combinations not used (or no longer used) in clinical 
practice should also be included (Table 2). By contrast, 
certain antibiotics largely prescribed in human therapy 
should not be tested in vitro, since they consistently 
provide misleading results as to their efficacy both in 
vitro and in vivo (Table 3) .  Adequate use of these drugs 
should be based on the testing of other members of the 
family (Table 1). 
These various technical or biological constraints 
favor fixed menus that can vary depending upon the 
Gram stain, the species, or the site of isolation of the 
bacterial pathogen. As far as possible, they should 
include the antibiotics that are currently most 
prescribed. Exerting a selective pressure, these drugs are 
likely to detect early emergence of resistance. Provided 
that they are composed by experts, these menus are 
likely to be more judicious than those established by 
Table 3 
tested 
Antibiotics used in therapy that should not be 
Antibiotic Microorganism 
Penicillins (except benzylpenicillin) Staphylococcus 
Cloxacillin, dicloxacillin, 
flucloxacillin, nafcillin 
Cephalosporins 
Clindamycin 
Amikacin 
Netilmicin 
Gram-positive cocci 
Penicillins susceptible to penicillinases Haemophilus', Nersreria 
(except benzylpenicillin) 
Topical drugs 
Prodrugs 
All bacteria 
~ 
'Except against strains that are intermediate or resistant to 
penicillins and do not produce a penicillinase. 
microbiologists, who conduct in vitro antibiotic 
susceptibility tests (the antibiogramme) only occasion- 
ally. They avoid redundancy and contribute to the 
standardization of in vitro tests, a prerequisite for 
comparison of results, epidemiologic studies and 
efficient quality control. The rigidity in the antibiotic 
assortment should not preclude the possibility of adding 
antibiotics that are necessary under certain circum- 
stances (due to the patient, the bacterium or the 
environment), for evaluation of new drugs or for 
specific epidemiologic studies. 
The antibiotic family as a functional unit 
The relationship between bacteria and antibiotics is 
best defined at the species level. This is due to the fact 
that chromosomal intrinsic resistance, which results 
from lack of penetration, active efflux, lack of target for 
the antibiotic or production of a detoxift-ing enzyme, 
is species rather than genus, family or Gram-stain 
specific. In cases of acquired resistance this is due to a 
limited host range of the plasmids and to barriers in 
heterologous gene expression. On the other hand, and 
as already discussed, antibiotics belonging to the same 
group display similar spectra of activity and are subject 
to bacterial cross-resistance. For certain combinations 
of bacterial species and antibiotic class, it appears 
justified (and even advisable) to report a result for an 
entire family of antibiotics even though a single 
member has been tested in vitro (Table 1). 
Correct bacterial identification is required 
Because of the multiplicity of acquired and intrinsic 
resistances that are often combined, analysis, in terms 
of biochemical mechanisms, of resistance phenotypes is 
IMPLICATIONS
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almost impossible if the identity of the bacterial host is 
not known. In addition, the clinical relevance of a given 
resistance mechanism also depends upon the host. For 
instance, acquisition of MLS resistance by members of 
the famdy Enterobacteriaceae is far less important as 
compared to Gram-positive cocci. Finally, levels of 
phenotypic resistance achieved by the same determin- 
ant in different host cells can vary dramatically, being 
easily detectable in one species and barely detectable in 
another (for example, 6’-aminoglycoside acetyltrans- 
ferase determines in Pseudomonus a broad-resistance 
spectrum, whereas in Escherichia coli it confers resistance 
to only a few antibiotics). Fortunately, there are 
efficient techniques for rapid bacterial identification at 
the species level, which is required for interpretive 
reading of the in vitro antibiotic susceptibility tests (the 
antibiogramme). Conversely, species identification also 
leads to identification of intrinsic resistance mech- 
anisms, e.g. 6’-aminoglycoside acetyltransferase in 
Enterococcus faecium and Serratia, 2’-amino-glycoside 
acetyltransferase in Providencia, and 3’-aminoglycoside 
phosphotransferase or active efflux in I? aeruginosa. 
Not all medical microbiologists are experts in antibiotics 
Since interpretive reading of in vitro antibiotic 
susceptibility tests (the antibiogramme) requires an 
immense knowledge of antibiotics (chemical structure 
and mode of action, mechanisms of resistance and 
corresponding phenotypes, intrinsic resistance, fluid 
and tissue pharmacokinetics, metabolism, MIC distri- 
bution of bacterial populations, correlation between 
in vitro results and therapeutic outcome, etc.), this 
approach remains the domain of a few experts. As a 
matter of fact, because of the amount of information 
required, interpretive reading is best achieved by 
computerized expert systems. Several of these systems 
have been developed in recent years in France and are 
used for routine work or for teaching purposes. 
Fortunately, the rapid spread of automated sus- 
ceptibility devices and of computers in clinical 
laboratories wdl, no doubt, favor the popularization of 
artificial intelligence applied to the evaluation of 
antibiotic activity, which should result in improved 
quality and safety of in vitro tests and better education 
of medical microbiologists. 
Not all antibiotic resistance mechanisms are known 
Obviously one can only routinely analyze resistance 
mechanisms that have been previously reported. 
Interpretive reading, by utilizing bacterial identification 
and antibiotic susceptibility, is the most efficient way to 
detect unknown mechanisms. It draws attention to 
codbcting results that have to be verified. If confirmed, 
the discrepancy may be due to a ‘new’ mechanism that 
does not phenotypically mimic an ‘older’ one. 
Detection of new mechanisms of resistance leads to 
reconsideration of breakpoints for clinical categoriz- 
ation (e.g. reduction of the low breakpoint of penicillin 
for pneumococci) and thus contributes to improve- 
ments in in vitro methods. Interpretation of resistance 
phenotypes is based on the comparison of clinical 
isolates with ‘prototype’ susceptible bacteria belonging 
to the same species. It is therefore easier to perform 
with bacteria possessing a single resistance mechanism 
per class of antibiotic. However, coexistence of various 
mechanisms conferring resistance to the same group of 
drugs is common in human pathogens. As already 
discussed, this does not constitute a problem, since, in 
the majority of the cases studied so far, these 
mechanisms act synergistically and confer high-level 
resistance that is readdy detectable. A remaining 
limitation is intrinsic resistance of new opportunistic 
pathogens that has not yet been totally explored. 
Biochemical and clinical resistances are not synonymous 
Biochemical resistance is secondary to mutations or 
acquisition of exogenous DNA and refers to the 
parental strain considered as susceptible. It does not 
always correlate with clinical resistance. For example, 
Escherichia coli produces a chromosomal cephalo- 
sporinase and, although amino-, carboxy-, and acyl- 
ureidopenicillins and cephalosporins are less active 
against this species, these antibiotics remain active in 
therapy. Conversely, staphylococci, Haemophilus, and 
gonococci that produce a penicillinase should be 
considered as clinically resistant, irrespective of their 
MIC. 
Permeability mutants and active efflux 
Antibiotic resistance through production of a 
detoxifying enzyme entails resistance to antibiotics of 
the same class. Usually, the MICs of antibiotics that are 
substrates are high whereas those of antibiotics that are 
not modified remain low, resulting in an enzymatic ‘in 
vivo substrate profile’ that is easily recognizable. By 
contrast, mutations in porins or in lipopolysaccharide 
that alter permeability of the cells and active efflux of 
the drugs can confer low-level cross-resistance to 
structurally unrelated antibiotics such as p-lactams, 
chloramphenicol, quinolones, tetracycline and tri- 
methoprim. This pathway to resistance is therefore 
difficult to detect in vitro, and also by molecular 
techniques that are not suited for detection of point 
mutations. In a few instances, certain antibiotics that are 
more affected can help in detecting this type of 
resistance (Table 2) .  
LIMITATIONS
IMPLICATIONS
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CONSEQUENCES 
Individualization of bacterial species 
For reasons already considered, interpretation of in 
vitro antibiotic susceptibility tests (the antibiogramme) 
cannot be dissociated from bacterial identification. For 
example, the modal MIC of ampicillin for susceptible 
pneumococci is 0.01 pg/mL and these bacteria are 
considered as resistant when the MIC is 20.1 p g / d ,  
whereas MICs of the same antibiotic for susceptible E. 
coli strains are 2 to 4 p g / d .  Conversely, groups of 
bacteria need to be individualized for optimum in vitro 
study (i.e. staphylococci, streptococci, enterobacteria, 
Pseudomonas, Haemophihr, Gram-positive anaerobes 
and Gram-negative anaerobes). For each group of 
microorganisms, different antibiotics have to be tested 
and various breakpoints should be used. This necessity 
is recognized, at least in part, by the various national 
committees for antimicrobial susceptibility testing. 
However, this subdivision represents an additional 
degree of complexity for analysis of the results that, 
again, can be best handled by expert systems. 
Aid in bacterial identification 
If proper identification is required for analysis of 
susceptibility tests, conversely, intrinsic resistance can 
be extremely useful in correcting or confirming 
bacterial identification. This is the reason why certain 
antibiotics that often do not constitute the best choice 
in therapy should be tested in vitro against particular 
species or genera (Table 4). 
Improved and permanent quality control 
Together with reports of more logical results, a major 
outcome of interpretive reading of in vitro antibiotic 
susceptibility tests (the antibiogramme) is the establish- 
ment of continuous quality control. This is due to (1) 
simultaneous analysis of identification and antibiotic 
susceptibility profile of the clinical isolate that ensures 
coherence between the two types of results obtained 
independently with different techniques, and (2) 
critical interpretation of the resistance phenotype 
observed. This quality control is complementary to the 
technical one with recommended test strains. 
Impossible phenotypes 
The so-called impossible phenotypes, although almost 
anything is possible in biology, correspond to resistance 
phenotypes that have not yet been observed in nature 
(Table 5 ) .  They are the result of intrinsic resistance or 
susceptibility but also of cross-resistance and co- 
resistance to antibiotics. Their discovery implies that at 
least one of each identification or drug susceptibility 
should be rechecked. Impossible phenotypes, if they do 
Table 4 Antibiotics useful for bacterial identification. 
Antihiotic Microorganism 
Amino-, carboxypenicillins 
Aminopenicillins, 
first-generation 
cephalosporins 
Cefoxitin 
Cefalotin, Cefotaxime 
Clavulanic acid 
Sulbactam 
Imipeneni 
Aminoglycosides 
Tetracycline 
Lincomycin 
Bacitracin 
Colistin 
Trimethoprim 
Nitrofurans 
Novobiocin 
Fosfomycin 
Vancomycin 
Metronidazole 
Optochin” 
O /  1 29d 
Citrobacter diverstrs, Klebsiella 
Citrobacterfreundii, Etzterobacter, 
Movanella, Proteus v d p r i s ,  
Providencia, Serratia 
C. freundii, Clostridium dijficile, 
Enterobacter 
Bacillus 
Campylobacter 
Acinetobacter, Pseudomonas cepacia 
Xantkomonas maltoplzilia 
I? cepacia, l? maltuphilia, streptococci, 
anaerobes 
Proteus mirabilis 
Eikenella corrodens, Ew terococcus faecalis, 
Haemophilus, Staphylococcus xylosus, 
Listeria, Neisseria, Gram-negative 
bacteria 
Streptococcus pyqenrs  
Sensitivity: l? aeruxinosa 
Resistance: Proteus, Providencia, 
Serratia, I? cepacia, Gram-positive 
bacteria 
Acinetobacter, Brucella spp., 
Campylobacter, Neisseria, Nocardia, 
Pseudomonas spp. 
Proteus, Providencia, Acinetobacter, 
micrococci 
Staphylococcus saprophytieus 
Acinetobacter, S. saproplryticus 
Erysipelothrix rhusopathiae, Lactobacillus, 
Leuconostoc, Nocardia, Pediococcus, 
Gram-negative bacteria 
Cardnerella vaginalis, Propionibacterrum, 
aerobes 
Pneumococci 
Differentiation Micrococcns, 
Differentiation enterobacteria, 
Staphylococcus 
Pasteurella, Vibrio 
“Not used in therapy 
not correspond to a new resistance mechanism, reflect 
erroneous identification or susceptibility testing, or a 
mixed culture. 
Abnormal and isolated resistance or susceptibility 
In this case, a single resistance or susceptibdity character 
does not fit with the other results. This anomaly is most 
often associated with a technical defect. For example, 
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Table 5 Examples of impossible antibiotic resistance phenotypes 
Resistance phenotype Microorganism 
GentamicinR, other aminoglycosidesS Gram-positive cocci 
MinocyclineR, tetracyclineS 
Methicillin or oxacillinR, cephalosporins or carhapenem’ 
Methicillin or oxacillinR, penicillins 
PenicillinR 
TeicoplaninR, vancomycin’ 
Staphylococcus aureus 
Group A, C, G streptococci 
Enterococci 
Amino-, carboxypenicillinss Citrobacter diuersus 
Aminopenicillinss, first-generation cephalosporinss, Citrobacterjeundii, Enterobacter cloacae, Morganella 
aminopenicillin+clavulanic acidS (except Proteus penneri and I? vulgaris) morpnii, Proteus vulgaris, Providencia, Serratia, Yersinia 
Cefamandole or cefuroximeS 
Cefoxitin’ Citrobacterjeundii, Enterobacter 
l? uul,,ris, Serratia 
Third-generation cephalosporinsR, amino-, carboxypenicillins? 
and/or first-generation cephalosporins’ 
Enterobacteriaceae 
Colistin’ Proteus, Prouidencia, Serratia 
microorganisms susceptible to amoxicillin and resistant 
to the combination amoxicillin plus clavulanic acid or 
enterobacteria resistant to imipenem attest to antibiotic 
instability. 
High incidence of rare phenotypes 
Rare phenotypes (Table 6) represent resistance 
mechanisms that either have been recently detected or 
that have not been epidemiologically successful (e.g. 
4‘-aminoglycoside nucleotidyltransferase in entero- 
cocci, lincosamide nucleotidyltransferase in S. aureur). 
Apart from strain epidemics, for which they constitute 
an excellent marker, a sudden change in their incidence 
is suspect. For example, frequent isolation of strains of 
Staphylococcus resistant to lincomycin suggests that the 
Gram-positive cocci examined may well be, in fact, 
enterococci, whereas numerous Enterococcus faecium 
strains resistant to low levels of vancomycin evoke 
Enterococcus gallinarum or E. casselij-lavus-jlavescens. A 
high number of isolates of various species resistant to 
trimethoprim should lead us to verifjl the thymidine 
content of the culture medium. Of course, the notion 
of rarity is relative and varies with the ecosystem 
considered. Enterococci resistant to penicdhn through 
production of a penicillinase are encountered with 
increasing frequency in North and South America, 
whereas they have not yet been reported in Europe. 
Also, one does not expect a similar prevalence of 
resistance determinants in patients from intensive care 
units and in members of rural communities. 
Table 6 
Phenotype Microorganism 
Examples of rare antibiotic resistance phenotypes 
Isolated resistance to lincosamides 
Isolated resistance to tobramycin 
Streptogramin resistance 
Teicoplanin resistance 
Resistance to cefotaxime-ceftriaxone 
Penicillin resistance through 
penicillinase productiona 
Isolated resistance to gentamicin 
Isolated resistance to tobramycin 
Glycopeptide resistance” 
Carbapenem resistance 
Resistance to third-generation 
cephalosporins 
Aztreonam resistance 
Amikacin resistance 
Amino-, carboxypenicillin 
susceptibility 
Amikacin resistance+tobramycin 
susceptibility 
Penicillin resistance through 
penicillinase production 
5-Nitromidazole resistance 
Staphylococcus aureus 
Streptococcus pneumoniae 
Enterococci 
Acinetobacter, enterobacteria, 
Barfemides jagi t is  
Escherichia coli, 
Proteus mirabilis, 
Providencia stuartii, 
Salmonella 
Klebsiella 
Pseudomonns aeruginosa 
Neisseria meningitidis 
‘Outside North America. 
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Epidemiology of resistance characters 
The reasoning in terms of biochemistry substitutes the 
study of incidence of resistance mechanisms for that of 
resistance to isolated drugs. This approach is much 
more subtle and informative. It explains, for example, 
co-selection of resistances due to cross-resistance and 
showed how antibiotics restricted to veterinary use can 
select mechanisms found later in clinical isolates where 
they confer resistance to drugs used in human therapy 
(e.g. gentamicin resistance by production of a 3- 
aminoglycoside acetyltransferase selected by apramycin; 
Table 2). 
GENOTYPIC DETECTION OF RESISTANCE 
As already discussed, there are certain limitations to 
interpretative reading of the in vitro antibiotic suscepti- 
bility tests (the antibiogramme) which, in fact, con- 
stitute indications to detection of resistance at  the 
genotypic level. 
Detection of resistance in the absence of growth 
Because the detection level of molecular biology 
techniques can be as low as a single gene copy, 
genotypic detection of resistance is effective against 
non-growing and even dead bacteria (Table 7). This 
not only provides results that could not be obtained by 
another approach (e.g. for in vivo cultivable bacteria) 
but also improves the safety in the laboratory when one 
is dealing with ‘dangerous’ bacteria. Another major 
advantage of these techniques is the rapidity since the 
results can be obtained in a few hours. 
Detection of inducible or low-level resistance 
Glycopeptide resistance in enterococci represents a 
good example of the indications of detection of 
resistance at  the genome level. There are three types of 
resistance, VanA, VanB and VanC, each being difficult 
to detect phenotypically. The VanA type, which is 
high-level resistance to both vancomycin and 
teicoplanin, should be in principle easily detected 
phenotypically. However, resistance of this type is 
slowly inducible by glycopeptides, which explains why 
VanA resistance cannot be detected by rapid automated 
systems. In addition, this resistance is expressed at 
various levels when transferred to other bacterial 
genera. The latter observation may well account, at  
least in part, for the delay in detection of this type of 
resistance in other bacterial species. The VanB type of 
resistance is even more difficult to detect, since not only 
is it inducible but it also confers various levels of 
resistance, which can be very low, to vancomycin only. 
The VanC type is also a low level of resistance to 
vancomycin alone and is species specific. An approach 
Table 7 
growth 
Detection of resistance genes in the absence of 
Slow growers 
Myio bacterilr ni spp. 
Fastidious bacteria 
Anaerobes, B. !yydo$ri, Campylohartrr spp., capnophilic Gram 
negatives (Hnen~op/iilus spp.. Candiobacterilrnr /ronrini.c, Artinobacter 
attiiiomyietrmairlrita~is, Eihenella iorrodctir, Kin(qe1la kicr‘yae) , Bartoriella 
qnirrtana, Clilamydiii spp., Helimbniter pylon, Lqiuirrlla pnei~mop/iila, 
L q t o y i r a  spp., Myroplarma spp., Neiwria spp., Rur/ioli,rea Irriirt~lai~, 
Streptoioirlrs pnnrmoniar, I Jreaplarma rtrealyticunr 
In vivo cultivable bacteria 
RickEttsia, Tr iprema  spp. 
‘Dangerous’ bacteria 
Bntcel/a spp., E tirlaremis. M .  tubercrrlosii. 
based on selective amplification by the polymerase 
chain reaction of genes involved in vancomycin 
resistance has been developed. This technique allows 
not only rapid, sensitive and specific detection of 
glycopeptide resistance in enterococci but also 
identification of enterococci at  the species level, since, 
as already mentioned, resistance can be species specific. 
CONCLUSION: THE GOAL JUSTIFIES THE MEANS 
Extensive study of the biochemistry of bacterial 
resistance to antibiotics has had two major practical 
applications: (1) the design of new, semisynthetic, drugs 
that avoid resistance; and (2) a better Comprehension 
and hence better detection of resistance. 
In vitro antibiotic susceptibility tests (the antibio- 
gramme), like other tests in biology, should provide 
objective quantitative data, e.g. MICs. For various 
historical reasons, they also provide subjective inter- 
pretation of the data such as clinical categories. 
Interpretive reading of antimicrobial susceptibility tests 
is an attempt to reconcile these two notions by basing 
interpretation on the most recent knowledge in the 
field of antibiotic study, in particular that of 
mechanisms of resistance. The best that one can ask of 
antibiotic susceptibility testing is detection of resistance, 
in particular of low-level resistance. This can be 
achieved by improved interpretation of the results of in 
vitro sensitivity tests or by the design of certain 
genotypic approaches. The goal of the proposed 
approach is to provide the clinician with the necessary 
results for judicious decision-making in antibiotic 
therapy utilizing available information and to draw his 
or her attention to the combinations of bacteriutn and 
antibiotic for which there is a therapeutic risk. This 
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should result not only in better therapy but also in 
lower selection of bacterial resistance and, hence, 
longer half-life of antimicrobial agents. 
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